Mylan working with DCGI to launch new TB drug in India

Mylan working with DCGI to launch new TB drug in India

By, Admin 16 October 2019

Multinational pharmaceutical company Mylan is working with Drug Controller General of India (DCGI) to launch pretomanid, a medicine used to treat drug- resistant tuberculosis (TB), a top official of the US drug major has said. Non-profit drug developer TB Alliance and Mylan NV had in April announced a global collaboration to make the experimental drug pretomanid for cure of pulmonary tuberculosis. "We have submitted the new drug application to the office of DCGI. We are in an advanced stage of discussion and are working with the office of DCGI... Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylans global president and executive director Rajiv Malik told PTI during his recent visit to India. This drug is important for India because Prime Minister Narendra Modi said India would get rid of tuberculosis by 2025, he added. Also, Modi launched a campaign to eradicate TB from India by 2025, five years ahead of a globally-set deadline. TB Alliance was currently advancing the development of pretomanid in three ongoing late-stage clinical trials, Mylan had said in April.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!